logo

PROF

Profound Medical·NASDAQ
--
--(--)
--
--(--)
0.97 / 10
Underperform

Fundamental metrics for Profound Medical reveal significant concerns: Cash-MV and ROA (%) are negative, while Net cash flow from operating activities is highly negative. Profit-MV and Net income-Revenue show some strength, but the overall fundamental score is only 1.0/10. Historical back-tests indicate negative monthly returns for the current quartiles, underscoring weak financial health and constraining investment appeal.

Fundamental(0.97)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-1.64
Score3/3
Weight-4.96%
1M Return1.11%
ROA (%)
Value-61.13
Score0/3
Weight19.68%
1M Return-7.20%
Net cash flow from operating activities / Operating revenue (%)
Value-312.63
Score0/3
Weight17.61%
1M Return-6.20%
Profit-MV
Value0.47
Score2/3
Weight-14.21%
1M Return2.92%
Net income-Revenue
Value-0.15
Score2/3
Weight8.85%
1M Return-2.32%
Cash-UP
Value-0.05
Score2/3
Weight15.59%
1M Return-4.39%
Annualized net profit margin on total assets (%)
Value-81.50
Score0/3
Weight19.68%
1M Return-7.20%
Asset-MV
Value-0.51
Score0/3
Weight14.26%
1M Return-3.74%
Cash-MV
Value-0.07
Score1/3
Weight17.16%
1M Return-5.27%
Net profit / Total profit (%)
Value100.66
Score2/3
Weight6.35%
1M Return-1.55%
Is PROF fundamentally strong?
  • PROF scores 0.97/10 on fundamentals and holds a Premium valuation at present. Backed by its -74.32% ROE, -275.18% net margin, -5.73 P/E ratio, 7.33 P/B ratio, and 2.94% earnings growth, these metrics solidify its Underperform investment rating.